Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.
Haibel
Hildrun
H
Benjamin Franklin Hospital, Berlin, Germany.
Rudwaleit
Martin
M
Brandt
Henning C
HC
Grozdanovic
Zarho
Z
Listing
Joachim
J
Kupper
Hartmut
H
Braun
Jürgen
J
Sieper
Joachim
J
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012446:Sacroiliac Joint / Q000187:drug effects / Q000473:pathology; D012720:Severity of Illness Index; D013131:Spine / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab